Apexigen racks up $73 mln
Apexigen Inc, a biopharmaceutical company, has closed its Series B and Series C funding rounds at a total of $73 million. Decheng Capital led the $15 million Series B round while 3E Bioventures Capital, Virtus Inspire Ventures and SV Tech Ventures led the $58 million Series C round.
9 August 2018•1 min read
